HRT in difficult circumstances: are there any absolute contraindications?

References

• MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. The Cochrane Database of Systematic Reviews 2004; Issue 4. Art.No.:CD002978.DOI: 10.1002/14651858.CD002978.pub2
   PubMedGoogle Scholar
• MacLennan AH. Evidence-based review of therapies at the menopause. Int J Evid Based Healthc 2009;7:112–23
   PubMedGoogle Scholar
• Nelson HD, Vesco KK, Haney E, et al. Non-hormonal therapies for menopausal hot flashes: systematic review and metaanalysis. JAMA 2006;295:2057–71
   PubMed Web of Science ®Google Scholar
• Stearns V. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal symptoms. Treat Endocrinol 2006;5:83–7
   PubMedGoogle Scholar
• Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlaflaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877–90
   PubMed Web of Science ®Google Scholar
• Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety and tolerability of fixed-dose desvenlaflaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243–53
   PubMed Web of Science ®Google Scholar
• Reddy SY, Warner H, Guttuso T, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41–8
   PubMed Web of Science ®Google Scholar
• Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flushes: a randomised controlled trial. Menopause 2008;15:310–18
   PubMed Web of Science ®Google Scholar
• Board of the International Menopause Society. International Menopause Society updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181–94
   PubMed Web of Science ®Google Scholar
• White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17β-estradiol, a novel hormone treatment in post-menopausal women with stage 1 hypertension. Circulation 2005;112:1979–84
   PubMed Web of Science ®Google Scholar
• Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative hormone trial. Diabetologica 2004;47:1175–87
   PubMed Web of Science ®Google Scholar
• Bonds DE, Lasser NL, Qi L, et al. The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial. Diabetologia 2006;49:459–68
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. for the executive of the Endocrine Society. Postmenopausal Hormone Therapy. An Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2010;95(Suppl 1):S1–66
   Web of Science ®Google Scholar
• MacLennan AH, Sturdee DW. The ‘bioidentical/bioequivalent’ hormone scam. Climacteric 2006;9:1–3
   PubMed Web of Science ®Google Scholar
• Zhou B, Sun Q, Cong R, et al. Hormone replacement therapy and ovarian cancer risk: A meta-analysis. Gynecol Oncol 2008;108:641–51
   PubMed Web of Science ®Google Scholar
• Morch LA, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard Ø. Hormone therapy and ovarian cancer. JAMA 2009;302:298–305
   PubMed Web of Science ®Google Scholar
• Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women's Health Initiative randomized trial. JAMA 2003;290:1739–48
   PubMed Web of Science ®Google Scholar
• Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy; a systematic review. Gynecol Oncol 2004;92:827–32
   PubMed Web of Science ®Google Scholar
• Mascarenhas C, Lambe M, Bellocco R, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 2006;119:2907–15
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Singh P, Oehler MK. Hormone replacement after gynaecological cancer. Maturitas 2010;65:190–7
   PubMed Web of Science ®Google Scholar
• Hinds L, Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int 2010;16:89–93
   PubMedGoogle Scholar
• Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006;9:49–58
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial plus progestin. Maturitas 2006;55:103–5
   PubMed Web of Science ®Google Scholar
• Aupperlee M, Kariagina A, Osuch J, Haslam SZ. Progestins and breast cancer. Breast Dis 2005/2006;24:37–57
   PubMedGoogle Scholar
• Antoine C, Liebens F, Carly B, Pastijn A, Neusy S, Rozenberg S. Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod 2007;22:616–22
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM, et al. on behalf of the HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475–82
   PubMed Web of Science ®Google Scholar
• von Schoulz E, Rutqvist LE, on behalf of the Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial. J Natl Cancer Inst 2005;97:533–35
   PubMed Web of Science ®Google Scholar
• Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer 2009;126:483–89
   Web of Science ®Google Scholar
• Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing system in breast cancer patients. Fertil Steril 2008;90:17–21
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Sturdee DW. Is endometrial monitoring required with the use of long-term unopposed vaginal oestrogen? Climacteric 2006;9:321–22
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697–708
   PubMed Web of Science ®Google Scholar
• Kennemans P, Bundred NJ, Foidart J, et al. for the Liberate Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–46
   PubMed Web of Science ®Google Scholar
• Rippy L, Marsden J. Is HRT justified for symptom management in women at higher risk of developing breast cancer? Climacteric 2006;9:404–15
   PubMed Web of Science ®Google Scholar
• Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002;20:699–706
   PubMed Web of Science ®Google Scholar
• Sellars TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973–80
   PubMed Web of Science ®Google Scholar
• Gramling R, Eaton CB, Rothman KJ, Cabral H, Silliman RA, Lash TL. Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women. Epidemiology 2009;20:752–6
   PubMed Web of Science ®Google Scholar
• Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRACA1 or BRACA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967–75
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Friebel T, Wagner T, et al. for the PROSE study group. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRACA1 and BRACA2 mutation carriers: the PROSE study group. J Clin Oncol 2005;23:7804–10
   PubMed Web of Science ®Google Scholar
• Eisen A, Lubinski J, Gronwald J, et al. for the Hereditary Breast Cancer Study Group. Hormone therapy and the risk of breast cancer in BRACA1 mutation carriers. J Natl Cancer Inst 2008;100:1361–7
   PubMed Web of Science ®Google Scholar
• Karagas MR, Stukel TA, Dykes J, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002;86:1085–9
   PubMed Web of Science ®Google Scholar
• MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer 2004;90:770–2
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573–80
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–2
   PubMed Web of Science ®Google Scholar
• Straczek C, Oger E, de Jonage-Canonico MBY, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Impact of the route of administration. Circulation 2005;112:3495–500
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Conrad J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006;4:1259–65
   PubMed Web of Science ®Google Scholar
• Toh S, Hermadez-Diaz S, Logan R, Rossouw JE, Herman MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010;152:211–17
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006;166:357–65
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605–13
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'Aniello S, Garbe E, Suisse S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
   PubMed Web of Science ®Google Scholar
• Yang CH, Lee JN, Hsu SC, Kuo CH, Tsai EM. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women – a 3-year study. Maturitas 2002;43:35–9
   PubMed Web of Science ®Google Scholar